Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

CS First Boston Lowers Myriad Genetics to 'Neutral'

Credit Suisse First Boston downgraded Myriad Genetics (MYGN) to neutral from outperform.

Analyst Mark Augustine says the fourth-quarter results were disappointing. He notes predictive medicine sales are up 22% year over year, but essentially flat sequentially. Augustine widened the 86-cent fiscal 2004 (June) loss estimate to a $1.00 loss. He cut the $14 to $16 target range to $11 to $13.

He says he's waiting for benefits to emerge from a DTC campaign that ended earlier this year. Also, Augustine notes the critical-to-long-term predictive medicine uptake will be supportive clinical studies that could help establish optimal ways to manage individuals at increased risk for breast and ovarian cancer.

blog comments powered by Disqus